MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects

Alzheimer disease (AD) results, in part, from the excess accumulation of the amyloid-β (Aβ) peptide as neuritic plaques in the brain. The short Aβ peptide is derived from the large transmembrane Aβ precursor protein (APP). The rate-limiting step in the production of Aβ from APP is mediated by the β-...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry Vol. 289; no. 8; p. 5184
Main Authors: Long, Justin M, Ray, Balmiki, Lahiri, Debomoy K
Format: Journal Article
Language:English
Published: United States 21.02.2014
Subjects:
3' Untranslated Regions - genetics
Aged
Aged, 80 and over
Alzheimer Disease - enzymology
Alzheimer Disease - genetics
Alzheimer Disease - pathology
Amyloid beta-Peptides - metabolism
Amyloid Precursor Protein Secretases - genetics
Argonaute Proteins - metabolism
Aspartic Acid Endopeptidases - genetics
Base Sequence
Brain - pathology
Cell Line, Tumor
Cell Shape
Cells, Cultured
Computational Biology
Conserved Sequence - genetics
Demography
Down-Regulation - genetics
Female
Gene Knockdown Techniques
Humans
Male
MicroRNAs - genetics
MicroRNAs - metabolism
Molecular Sequence Data
Protein Binding - genetics
Reproducibility of Results
Time Factors
Gene Regulation
Noncoding RNA
MicroRNA
Secretases
β-Peptide
Aging
Alzheimer Disease
Human Neuron
Dementia
Human Brain Tissue
ISSN:1083-351X, 1083-351X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer disease (AD) results, in part, from the excess accumulation of the amyloid-β (Aβ) peptide as neuritic plaques in the brain. The short Aβ peptide is derived from the large transmembrane Aβ precursor protein (APP). The rate-limiting step in the production of Aβ from APP is mediated by the β-site APP-cleaving enzyme 1 (BACE1). Dysregulation of BACE1 levels leading to excess Aβ deposition is implicated in sporadic AD. Thus, elucidating the full complement of regulatory pathways that control BACE1 expression is key to identifying novel drug targets central to the Aβ-generating process. MicroRNAs (miRNAs) are expected to participate in this molecular network. Here, we identified a known miRNA, miR-339-5p, as a key contributor to this regulatory network. Two distinct miR-339-5p target sites were predicted in the BACE1 3'-UTR by in silico analyses. Co-transfection of miR-339-5p with a BACE1 3'-UTR reporter construct resulted in significant reduction in reporter expression. Mutation of both target sites eliminated this effect. Delivery of the miR-339-5p mimic also significantly inhibited expression of BACE1 protein in human glioblastoma cells and human primary brain cultures. Delivery of target protectors designed against the miR-339-5p BACE1 3'-UTR target sites in primary human brain cultures significantly elevated BACE1 expression. Finally, miR-339-5p levels were found to be significantly reduced in brain specimens isolated from AD patients as compared with age-matched controls. Therefore, miR-339-5p regulates BACE1 expression in human brain cells and is most likely dysregulated in at least a subset of AD patients making this miRNA a novel drug target.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1083-351X
1083-351X
DOI:10.1074/jbc.M113.518241